Antisense Therapeutics Limited (ASX code: ANP) is an Australian publicly traded pharmaceutical drug discovery and development company whose mission is to create, develop and commercialise novel antisense therapeutics.

Antisense Therapeutics' strategy is:

• to create antisense drugs for diseases where there are large and/or poorly met markets, in collaboration with Antisense Therapeutics’ technology and research partners

• to out-source preclinical and clinical testing of the candidate drugs to expert contractors

• to commercialise the drugs that are shown to be successful in pre-clincal and/or clinical testing by entering into licensingdeals or other partnerships with major pharmaceutical companies.
Antisense Therapeutics (ASX:ANP)
Company Directors
Mr Chris Belyea (Non Exec. Director)
Mr George Werther (Non Exec. Director)
Prof. Graham Mitchell (Non Exec. Director)
Mr Mark Diamond (Managing Director, CEO)
Mr Phillip Hains (CFO)
Mr Robert Moses (Chairman)
Mr Simon Watkin (Investor Relations)
Contact Information
Phone: + 61 3 9827 8999
Website:

Address
Level 1, 10 Wallace Avenue Toorak, VIC, Australia, 3142
Media Releases
Latest Company News
No news item available for the company